Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05IHU
|
||||
Former ID |
DIB002792
|
||||
Drug Name |
Tetrahydrozoline
|
||||
Synonyms |
Tyzine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Ocular disease [ICD10:H00-H59] | Approved | [1] | ||
Company |
Fougera Pharmaceuticals Inc
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C13H17ClN2
|
||||
Canonical SMILES |
C1(c2c(CCC1)cccc2)C1=NCCN1
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [1], [2] | |
KEGG Pathway | cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Reactome | Adrenoceptors | ||||
Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
Adrenaline,noradrenaline inhibits insulin secretion | |||||
G alpha (i) signalling events | |||||
G alpha (z) signalling events | |||||
Surfactant metabolism | |||||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
Platelet Aggregation (Plug Formation) | |||||
Integration of energy metabolism | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. | ||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.